Skip to content

Triphase announces Health Canada approval to initiate Marizomib Phase 1 study in recurrent glioma patients

Triphase-logo-WebTORONTO and SAN DIEGO (September 25, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that it has received approval from Health Canada to initiate its Phase 1 clinical study of marizomib in combination with bevacizumab (Avastin®) in patients with recurrent malignant glioma in Canada. Marizomib is a novel and highly potent proteasome inhibitor that readily penetrates the blood brain barrier. It prevents the breakdown of proteins involved in signal transduction, which inhibits tumor growth.

The study will be conducted in Canada at the Princess Margaret Hospital in Toronto and led by principal investigator Warren Mason, M.D., medical director of the Brain Tumour Centre and Kirchmann Family Chair in Neuro-oncology Research at Princess Margaret Hospital.

“Malignant gliomas are rarely curable, and the prognosis for patients with high-grade gliomas is generally poor. One of the few treatment options currently available for recurrent gliomas is bevacizumab. As a result, new treatment options are urgently needed for patients suffering from this universally fatal disease,” said Dr. Mason. “Published literature indicates that targeting the proteasome in glioma cells has shown significant anti-tumor activity. Given that marizomib is a first-in-class pan-proteasome inhibitor that is brain penetrant, I am looking forward to evaluating this combination regimen in my patients.” 

Continue Reading

Sunnybrook forms new industry partnership to advance WaveCheck technology

Co-development agreement, brokered by MaRS Innovation, to advance ultrasound chemotherapy monitoring technology as clinical tool

WavecheckTORONTO (March 12, 2015) — Sunnybrook Health Sciences Centre and MaRS Innovation today announced a co-development agreement for WaveCheck, an ultrasound technology that transforms conventional equipment so that physicians can monitor a breast cancer tumour’s response to chemotherapy.

This announcement was covered in Biotechnology Focus, Aunt Minnie.com (radiology blog), dotmed.com, Bio-Medicine.org, Bloomberg Business and Research Views.

The partnership with GE Healthcare, brokered by MaRS Innovation, seeks to develop WaveCheck as a clinical tool that gives clinicians rapid, improved transparency to determine if breast cancer tumors are responding to chemotherapy.

WaveCheck is a clinical technique invented, refined and tested by Dr. Gregory Czarnota, chief of Radiation Oncology at Sunnybrook’s Odette Cancer Centre, and Michael C. Kolios, professor of Physics and associate dean, Research and Graduate Studies, in Ryerson University’s Faculty of Science. Their technology uses ultrasound to visually demonstrate whether chemotherapy is destroying a breast cancer tumour at the beginning of chemotherapy treatment in as little as one week. If applied to the clinic, this knowledge has the power to transform patient experience, since existing breast cancer patients typically wait until the end of treatment, anywhere from four to six months, to know if their tumor has responded.

In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.
In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.

In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology shows promise as an accurate, efficient way to monitor tumour response, opening the door to tailored treatment.

The agreement leverages GE Healthcare’s extensive ultrasound technology and market expertise in bringing new ultrasound innovations to global hospitals and clinics with Sunnybrook’s leadership in oncology research and cancer care through the Odette Cancer Centre.

Continue Reading

AvidBiologics and National Research Council of Canada to collaborate on antibody-drug conjugates

AvidBiologics Inc.Toronto-based AvidBiologics Inc., a leading Canadian biotech company, and the National Research Council of Canada (NRC) are collaborating on one of the most promising advances in the fight against cancer: antibody-drug conjugates (ADCs).

Recently signed research and licensing agreements will enable both organizations to continue developing a series of ADCs targeting breast, lung, and head-and-neck cancers. Unlike chemotherapy, ADCs specifically seek and destroy cancer cells, with minimal impact on healthy cells.

“The work performed by NRC is crucial to assembling the data package needed for clinical trials,” said Ilia A. Tikhomirov, president and CEO of Avid Biologics, which focuses exclusively on ADCs. “We are privileged to be able to continue the rapid development of our lead candidate while advancing the other candidates in the pipeline in collaboration with the NRC. We thank the NRC and all of our partners for their support as AvidBiologics transitions from a discovery-stage to a development-stage company.”

Continue Reading

Council of Academic Hospitals features WaveCheck technology and crowdfunding campaign

waveThe Council of Academic Hospitals of Ontario’s online magazine highlighted WaveCheck on February 3, 2014 as a more personalized approach to cancer treatments because of the technology’s ability to effectively monitor chemotherapy response.

WaveCheck’s technology, invented by Dr. Gregory Czarnota of Sunnybrook Health Sciences Centre and Professor Michael C. Kolios of Ryerson University, allows women and men undergoing chemotherapy for breast cancer to know if their treatment is working at the beginning of treatment (within one to four weeks) rather than at the end of treatment (typically four to six months).

Here’s an excerpt from the article:

Breast cancer is the most common cancer among Canadian women, excluding non-melanoma skin cancers. It is the second leading cause of death from cancer in women in this country. The Canadian Cancer Society estimated that, in 2013, 65 Canadian women would be diagnosed with breast cancer every day, totaling 23,800 women a year; and 14 Canadian women would die from breast cancer every day, totaling 5,000 women a year. According to the Canadian Breast Cancer Foundation, one in nine Canadian women is expected to develop breast cancer during her lifetime; one in 29 will die from it.

Continue Reading
Back To Top